ピルフェニドン
Based on 83 publication(s) in Google Scholar
Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.99%
- CAS 番号: 53179-13-8
- 分子式: C12H11NO
- 分子量:185.22
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Stem Cell Signaling Compound Library
HY-L017
-
TGF-beta/Smad Compound Library
HY-L018
-
Wnt/Hedgehog/Notch Compound Library
HY-L020
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Angiogenesis-Related Compound Library
HY-L088
-
Transcription Factor-Targeted Library
HY-L090
-
Targeted Diversity Library
HY-L099
-
Rare Diseases Drug Library
HY-L102
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
EMA-Approved Drug Library
HY-L116
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Osteogenesis Compound Library
HY-L131
-
Chemokine Compound Library
HY-L132
-
Cancer Stem Cells Compound Library
HY-L135
-
Withdrawn Drug Compound Library
HY-L140
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Cytokine Inhibitors Library
HY-L161
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
Anti-Aging Compound Library Mini
HY-L034M
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Anti-Brain Cancer Compound Library
HY-L188
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
RNA Binding Bioactive Compound Library
HY-L248
-
Lactylation Compound Library
HY-L249
MedChemExpress（MCE）の使用を引用している文献 Pirfenidone
More- Eur Respir J. 2025 Jan 9:2400615. [Abstract]
- Bioact Mater. 2023 Nov 22:33:262-278. [Abstract]
- J Exp Clin Cancer Res. 2021 Feb 9;40(1):62. [Abstract]
- Sci Adv. 2022 Jun 17;8(24):eabn4564. [Abstract]
- J Control Release. 2025 Sep 10:385:114005. [Abstract]
- Arthritis Rheumatol. 2023 Feb;75(2):305-317. [Abstract]
- J Exp Med. 2025 Aug 4;222(8):e20241174. [Abstract]
- Pharmacol Res. 2024 Sep 11:107407. [Abstract]
- Mater Today Bio. 2025 Apr 5:32:101729. [Abstract]
- Mater Today Bio. 2023 Apr 25:20:100643. [Abstract]
- Adv Healthc Mater. 2025 May 7:e2500101. [Abstract]
- Cell Death Dis. 2022 Jul 30;13(7):663. [Abstract]
- Acta Pharmacol Sin. 2025 May 14. [Abstract]
- Acta Pharmacol Sin. 2025 Jan;46(1):107-121. [Abstract]
- Acta Pharmacol Sin. 2023 Aug;44(8):1665-1675. [Abstract]
- Phytomedicine. 2025 Dec:149:157565. [Abstract]
- Phytomedicine. 2024 May 8:130:155687. [Abstract]
- Phytomedicine. 2023 Sep:118:154919. [Abstract]
- Phytomedicine. 2023 Apr:112:154707. [Abstract]
- Phytomedicine. 2022 Aug:103:154187. [Abstract]
- NPJ Sci Food. 2025 Dec 11;10(1):9. [Abstract]
- Br J Pharmacol. 2026 Jun 17.
- Clin Sci. 2025 Jul 31;139(14):809-824. [Abstract]
- Br J Pharmacol. 2025 Apr 13. [Abstract]
- J Transl Med. 2025 Jul 10;23(1):763. [Abstract]
- Biomed Pharmacother. 2021 Nov:143:112152. [Abstract]
- Cell Rep. 2025 Dec 10;44(12):116725. [Abstract]
- Clin Transl Med. 2022 Oct;12(10):e1036. [Abstract]
- JCI Insight. 2025 Nov 25:e196605. [Abstract]
- Mol Ther Nucleic Acids. 2023 Mar 10:32:94-110. [Abstract]
- JCI Insight. 2022 Jan 25;7(2):e141108. [Abstract]
- Cell Biol Toxicol. 2025 Jan 28;41(1):35. [Abstract]
- Eur J Med Chem. 2022 Feb 5:229:114061. [Abstract]
- Chin Med. 2023 Mar 30;18(1):33. [Abstract]
- Biochem Pharmacol. 2026 Aug;250(Pt 1):117940. [Abstract]
- Biochem Pharmacol. 2025 Apr 23:116959. [Abstract]
- Biochem Pharmacol. 2024 Nov 6;230(Pt 3):116613. [Abstract]
- J Ethnopharmacol. 2026 Jun 12:364:121537. [Abstract]
- J Ethnopharmacol. 2026 Apr 6:360:121174. [Abstract]
- J Ethnopharmacol. 2025 Aug 29:352:120227. [Abstract]
- J Ethnopharmacol. 2024 Aug 10:330:118226. [Abstract]
- J Ethnopharmacol. 2023 Nov 15:316:116704. [Abstract]
- Chem Biol Interact. 2022 Aug 1:362:109999. [Abstract]
- J Ethnopharmacol. 2019 Jun 28:238:111878. [Abstract]
- Mol Ther Oncol. 2025 Sep 2.
- Am J Respir Cell Mol Biol. 2021 Jul;65(1):54-69. [Abstract]
- Cells. 2023 Dec 8;12(24):2795. [Abstract]
- Inflammation. 2021 Oct;44(5):1803-1814. [Abstract]
- Int J Mol Sci. 2023 Jan 5;24(2):1019. [Abstract]
- Int Immunopharmacol. 2026 Jan 1;168(Pt 1):115811. [Abstract]
- Int Immunopharmacol. 2025 Sep 5:165:115469. [Abstract]
- Int Immunopharmacol. 2022 Aug:109:108805. [Abstract]
- Pharm Res. 2020 Feb 24;37(3):59. [Abstract]
- J Inflamm Res. 2025 Jun 26:18:8447-8475. [Abstract]
- ERJ Open Res. 2026.
- Sci Rep. 2025 Aug 1;15(1):28071. [Abstract]
- Biomedicines. 2021 Jul 21;9(8):853. [Abstract]
- ACS Pharmacol Transl Sci. 2025 Oct 6;8(11):3984-4000. [Abstract]
- ACS Pharmacol Transl Sci. 2025 May 9;8(6):1610-1626. [Abstract]
- Exp Cell Res. 2024 Sep 20:114255. [Abstract]
- Mol Med Rep. 2021 Nov;24(5):758. [Abstract]
- Basic Clin Pharmacol Toxicol. 2026 Jan;138(1):e70158. [Abstract]
- Pathol Res Pract. 2025 Aug:272:156095. [Abstract]
- Pathol Res Pract. 2019 Oct;215(10):152568. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2025 Feb;398(2):1665-1679. [Abstract]
- Pancreatology. 2022 Jun;22(5):553-563. [Abstract]
- Parasitology. 2021 Jun;148(7):767-778. [Abstract]
- Biomed Res Int. 2022 Feb 7;2022:8752325. [Abstract]
- Radiat Res. 2018 Oct;190(4):396-403. [Abstract]
- Int J Ophthalmol. 2023 Jan 30:2023:4798071. [Abstract]
- Integr Biol (Camb). 2022 Mar 21;14(1):1-12. [Abstract]
- bioRxiv. 2026 Jun 20.
- SSRN. 2025 Dec 3.
- SSRN. 2025 Dec 12.
- bioRxiv. 2025 Aug 29:2025.08.25.672225. [Abstract]
- SSRN. 2025 Jul 10.
- Patent. US20250221973A1.
- medRxiv. 2024 Jun 28.
- Friedrich-Alexander University Erlangen-Nuremberg. 2023 May 2.
- SSRN. 2023 Mar 3.
- SSRN. 3 Nov 2022.
- Research Square Print. 2022 Aug.
- Oncotarget. 2018 May 4;9(34):23462-23481. [Abstract]
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
IF
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
生物活性
TGF-β2[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HFL1 | IC50 |
0.71 μM
Compound: PIRF; NSC748456
|
Antifibrotic activity in HFL1 cells assessed as inhibition of cell viability after 48 hrs by sulforhodamine B assay
Antifibrotic activity in HFL1 cells assessed as inhibition of cell viability after 48 hrs by sulforhodamine B assay
|
[PMID: 26896707] |
| HFL1 | IC50 |
9148 μM
Compound: PFD
|
Antiproliferative activity against human HFL1 cells assessed as reduction in cell proliferation measured after 24 hrs by CCK-8 assay
Antiproliferative activity against human HFL1 cells assessed as reduction in cell proliferation measured after 24 hrs by CCK-8 assay
|
[PMID: 34355186] |
| MRC5 | IC50 |
1320 μM
Compound: pirfenidone
|
Anti-fibrotic activity in human MRC5 cells assessed as inhibition of TGF-beta1 induced total collagen deposition
Anti-fibrotic activity in human MRC5 cells assessed as inhibition of TGF-beta1 induced total collagen deposition
|
[PMID: 31884408] |
| MRC5 | IC50 |
14.44 mM
Compound: Pirfenidone
|
Antifibrotic activity in human MRC5 cells assessed as inhibition of cell growth after 24 hrs by MTT assay
Antifibrotic activity in human MRC5 cells assessed as inhibition of cell growth after 24 hrs by MTT assay
|
[PMID: 24332090] |
| NIH3T3 | IC50 |
13.72 mM
Compound: 1; PFD
|
Antiproliferative activity against TGFbeta-induced mouse NIH3T3 cells assessed as cell growth inhibition incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against TGFbeta-induced mouse NIH3T3 cells assessed as cell growth inhibition incubated for 48 hrs by CCK-8 assay
|
[PMID: 35694690] |
| NIH3T3 | IC50 |
454 μM
Compound: 1
|
Antiproliferative activity against mouse NIH/3T3 cells after 72 hrs by MTT assay
Antiproliferative activity against mouse NIH/3T3 cells after 72 hrs by MTT assay
|
[PMID: 28122457] |
Pirfenidone (PFD) reduces the protein levels of the matrix metalloproteinase (MMP)-11, a TGF-β target gene and furin substrate involved in carcinogenesis. These data define PFD or PFD-related agents as promising agents for human cancers associated with enhanced TGF-β activity[1]. In RAW264.7 cells, a murine macrophage-like cell line, Pirfenidone suppresses the proinflammatory cytokine TNF-α by a translational mechanism, which is independent of activation of the MAPK2, p38 MAPK, and JNK. In the murine endotoxin shock model, Pirfenidone potently inhibits the production of the proinflammatory cytokines, TNF-α, interferon-γ, and interleukin-6, but enhances the production of the anti-inflammatory cytokine, interleukin-10[2]. Pirfenidone (PFD) shows its inhibitory effects on the proliferation of HLECs. Cell proliferation is attenuated in the 0.3 mg/mL group after 24 hours compare with the control group (P=0.044). The effect is more apparent in the 0.5 mg/mL group at 24, 48, and 72 hours (P<0.05). The proliferation is almost completely inhibited with 1 mg/mL PFD at all the time-points (P<0.01)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 53179-13-8
-
性状 Solid
-
分子量 185.22
-
分子式 C12H11NO
-
Color White to light yellow
-
SMILES
O=C1C=CC(C)=CN1C2=CC=CC=C2
-
別名
Pirfenidone; AMR69
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (83)
-
Journal Impact Factor
-
Most Recent
-
Eur Respir J
Inhibition of AXL ameliorates pulmonary fibrosis via attenuation of M2 macrophage polarization. [Abstract]2025 Jan 9:2400615. PMID: 39788632 -
Bioact Mater
Alveolar macrophage phagocytosis-evading inhaled microgels incorporating nintedanib-PLGA nanoparticles and pirfenidone-liposomes for improved treatment of pulmonary fibrosis. [Abstract]2023 Nov 22:33:262-278. PMID: 38076650 -
J Exp Clin Cancer Res
HOXA10 mediates epithelial-mesenchymal transition to promote gastric cancer metastasis partly via modulation of TGFB2/Smad/METTL3 signaling axis. [Abstract]2021 Feb 9;40(1):62. PMID: 33563300 -
Sci Adv
Female reproductive life span is extended by targeted removal of fibrotic collagen from the mouse ovary. [Abstract]2022 Jun 17;8(24):eabn4564. PMID: 35714185
Pirfenidone purchased from MedChemExpress. Usage Cited in: Sci Adv. 2022 Jun 17;8(24):eabn4564. [Abstract]
Female mice (15 months old) were treated with pirfenidone via injection (250 mg/kg, ip; 4 days) or orally (500 mg/kg, po; 2 weeks) or with nintedanib (50 mg/kg, ip; 4 days) and compared to those treated with vehicle (Veh) and young (Y; 2 months old) controls.
Pirfenidone purchased from MedChemExpress. Usage Cited in: Sci Adv. 2022 Jun 17;8(24):eabn4564. [Abstract]
Female mice (12 months old) were treated with pirfenidone orally (500 mg/kg; 2 weeks; n = 12) or vehicle (n = 16) alongside young controls (n = 8), and ovarian fibrosis was assessed by PSR staining.
-
J Control Release
Pulmonary surfactant-based pirfenidone-loaded nanovesicles for inhalation therapy of idiopathic pulmonary fibrosis. [Abstract]2025 Sep 10:385:114005. PMID: 40618852 -
Arthritis Rheumatol
mTOR inhibition prevents coronary artery remodeling in a murine model of Kawasaki disease. [Abstract]2023 Feb;75(2):305-317. PMID: 36057112 -
J Exp Med
A multimorphic variant in ThPOK causes an inborn error of immunity with T cell defects and fibrosis. [Abstract]2025 Aug 4;222(8):e20241174. PMID: 40392549 -
Pharmacol Res
Suppression of ZEB1 by Ethyl caffeate attenuates renal fibrosis via switching glycolytic reprogramming. [Abstract]2024 Sep 11:107407. PMID: 39270946 -
Mater Today Bio
Novel anti-pyroptosis drug loaded on metal-organic framework for intervertebral disc degeneration therapy. [Abstract]2025 Apr 5:32:101729. PMID: 40275959
Pirfenidone purchased from MedChemExpress. Usage Cited in: Mater Today Bio. 2025 Apr 5:32:101729. [Abstract]
NPCs treated with different doses of PFD (5-320 μM) for 24 h
Pirfenidone purchased from MedChemExpress. Usage Cited in: Mater Today Bio. 2025 Apr 5:32:101729. [Abstract]
Pirfenidone (20 μM; 24 h) was used for calcein/PI detection in the above-mentioned treated NPCs (scale bar: 100 μm; n = 3).
-
Mater Today Bio
Albumin-based formononetin nanomedicines for lung injury and fibrosis therapy via blocking macrophage pyroptosis. [Abstract]2023 Apr 25:20:100643. PMID: 37214555
Pirfenidone purchased from MedChemExpress. Usage Cited in: Mater Today Bio. 2023 Apr 25:20:100643. [Abstract]
Pirfenidone (50 mg/kg; once every two days; 14 days) was administered. Representative transverse (top row) and coronal (bottom row) micro-CT scan images of the lungs in living mice were obtained.
-
Adv Healthc Mater
Tissue-Microenvironment-Responsive Self-Assembling Peptide Nanoshells Boost Pirfenidone Efficacy in the Treatment of Liver Fibrosis. [Abstract]2025 May 7:e2500101. PMID: 40331409 -
Cell Death Dis
Sestrin2 remedies podocyte injury via orchestrating TSP-1/TGF-β1/Smad3 axis in diabetic kidney disease. [Abstract]2022 Jul 30;13(7):663. PMID: 35908070 -
Acta Pharmacol Sin
GPR40 activation alleviates pulmonary fibrosis by repressing M2 macrophage polarization through the PKD1/CD36/TGF-β1 pathway. [Abstract]2025 May 14. PMID: 40369224 -
Acta Pharmacol Sin
Otilonium bromide ameliorates pulmonary fibrosis in mice through activating phosphatase PPM1A. [Abstract]2025 Jan;46(1):107-121. PMID: 39160244 -
Acta Pharmacol Sin
2023 Aug;44(8):1665-1675. PMID: 37016043 -
Phytomedicine
Chaihu shugan powder ameliorated chronic pancreatitis by reprogramming SMS2-mediated sphingolipid metabolism in M1 macrophages. [Abstract]2025 Dec:149:157565. PMID: 41308384 -
Phytomedicine
Icariside II modulates pulmonary fibrosis via PI3K/Akt/β-catenin pathway inhibition of M2 macrophage program. [Abstract]2024 May 8:130:155687. PMID: 38759312 -
Phytomedicine
Vincamine as an agonist of G protein-coupled receptor 40 effectively ameliorates pulmonary fibrosis in mice. [Abstract]2023 Sep:118:154919. PMID: 37392673 -
Phytomedicine
Qimai Feiluoping decoction inhibits mitochondrial complex I-mediated oxidative stress to ameliorate bleomycin-induced pulmonary fibrosis. [Abstract]2023 Apr:112:154707. PMID: 36805483 -
Phytomedicine
Endocannabinoid signalling/cannabinoid receptor 2 is involved in icariin-mediated protective effects against bleomycin-induced pulmonary fibrosis. [Abstract]2022 Aug:103:154187. PMID: 35667261 -
NPJ Sci Food
Haematococcus pluvialis ameliorates renal fibrosis by restoring mitophagy via PINK1-Parkin-p62-LC3 signaling. [Abstract]2025 Dec 11;10(1):9. PMID: 41381553 -
-
Clin Sci
The novel AT2 receptor ligand, β-Pro7 Ang III, induces equivalent anti-fibrotic effects to Compound 21 but broader anti-fibrotic effects than pirfenidone in mice with bleomycin-induced pulmonary fibrosis. [Abstract]2025 Jul 31;139(14):809-824. PMID: 40590236 -
Br J Pharmacol
Inhibition of sphingosine-1-phosphate receptor-2 attenuates idiopathic pulmonary fibrosis by preventing its binding to dapper1 in bronchial epithelial cells. [Abstract]2025 Apr 13. PMID: 40222913 -
J Transl Med
CCN5 negatively regulates TGF-β-induced endometriosis associated fibrosis through Wnt/β-catenin signaling via Smad3-dependent mechanism. [Abstract]2025 Jul 10;23(1):763. PMID: 40640862 -
Biomed Pharmacother
2021 Nov:143:112152. PMID: 34536758 -
Cell Rep
Cancer cells transfer invasive properties through microRNAs contained in collagen tracks. [Abstract]2025 Dec 10;44(12):116725. PMID: 41379613 -
Clin Transl Med
Inhibition of ROCK ameliorates pulmonary fibrosis by suppressing M2 macrophage polarisation through phosphorylation of STAT3. [Abstract]2022 Oct;12(10):e1036. PMID: 36178087 -
JCI Insight
ANGPTL8 links refeeding to monocyte dynamics and metabolic inflammation via the CCL5-CCR5 axis. [Abstract]2025 Nov 25:e196605. PMID: 41289013 -
Mol Ther Nucleic Acids
2023 Mar 10:32:94-110. PMID: 37020681 -
JCI Insight
Pirfenidone increases IL-10 and improves acute pancreatitis in multiple clinically relevant murine models. [Abstract]2022 Jan 25;7(2):e141108. PMID: 34847076 -
Cell Biol Toxicol
Targeting p38γ synergistically enhances sorafenib-induced cytotoxicity in hepatocellular carcinoma. [Abstract]2025 Jan 28;41(1):35. PMID: 39871031 -
Eur J Med Chem
Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents. [Abstract]2022 Feb 5:229:114061. PMID: 34954593 -
Chin Med
Protective effects of Qing-Re-Huo-Xue formula on bleomycin-induced pulmonary fibrosis through the p53/IGFBP3 pathway. [Abstract]2023 Mar 30;18(1):33. PMID: 36997948 -
Biochem Pharmacol
SIRT6 activation attenuates inflammatory-fibrogenic events, improves lung function and survival in experimental pulmonary fibrosis. [Abstract]2026 Aug;250(Pt 1):117940. PMID: 41916469 -
Biochem Pharmacol
Identification of pyrazole scaffold inhibitors targeting cyclin-dependent kinase 8 for potential use in pulmonary fibrosis. [Abstract]2025 Apr 23:116959. PMID: 40280247 -
Biochem Pharmacol
Yohimbine treatment improves pulmonary fibrosis by attenuating the inflammation and oxidative stress via modulating the MAPK pathway. [Abstract]2024 Nov 6;230(Pt 3):116613. PMID: 39515589 -
J Ethnopharmacol
Linderalactone attenuates pulmonary fibrosis by suppressing HIF-1α-associated ferroptotic stress. [Abstract]2026 Jun 12:364:121537. PMID: 41839300 -
J Ethnopharmacol
A novel polysaccharide from Qamgur (Brassica rapa L.) mitigates pulmonary fibrosis by regulating inflammatory, epithelial-mesenchymal transition, and fibrotic pathways. [Abstract]2026 Apr 6:360:121174. PMID: 41500353 -
J Ethnopharmacol
Erchen decoction alleviates silicosis by attenuating ferroptosis and fibrosis in alveolar macrophages via modulating the P53/HMOX1 pathway. [Abstract]2025 Aug 29:352:120227. PMID: 40617365 -
J Ethnopharmacol
Mimosa pudica L. extract ameliorates pulmonary fibrosis via modulation of MAPK signaling pathways and FOXO3 stabilization. [Abstract]2024 Aug 10:330:118226. PMID: 38670401 -
J Ethnopharmacol
2023 Nov 15:316:116704. PMID: 37257706 -
Chem Biol Interact
TH5487, a small molecule inhibitor of OGG1, attenuates pulmonary fibrosis by NEDD4L-mediated OGG1 degradation. [Abstract]2022 Aug 1:362:109999. PMID: 35654123 -
J Ethnopharmacol
Dahuang Zhechong Pill suppresses colorectal cancer liver metastasis via ameliorating exosomal CCL2 primed pre-metastatic niche. [Abstract]2019 Jun 28:238:111878. PMID: 30986521 -
-
Am J Respir Cell Mol Biol
Kindlin-2 Acts as a Key Mediator of Lung Fibroblast Activation and Pulmonary Fibrosis Progression. [Abstract]2021 Jul;65(1):54-69. PMID: 33761308 -
Cells
Daphnetin Alleviates Bleomycin-Induced Pulmonary Fibrosis through Inhibition of Epithelial-to-Mesenchymal Transition and IL-17A. [Abstract]2023 Dec 8;12(24):2795. PMID: 38132116 -
Inflammation
MLL3 Inhibits Apoptosis of Rheumatoid Arthritis Fibroblast-Like Synoviocytes and Promotes Secretion of Inflammatory Factors by Activating CCL2 and the NF-κB Pathway. [Abstract]2021 Oct;44(5):1803-1814. PMID: 33914205 -
Int J Mol Sci
Theophylline Attenuates BLM-Induced Pulmonary Fibrosis by Inhibiting Th17 Differentiation. [Abstract]2023 Jan 5;24(2):1019. PMID: 36674533 -
Int Immunopharmacol
Acetylshikonin alleviates pulmonary fibrosis through inhibition of the STAT3 signaling pathway. [Abstract]2026 Jan 1;168(Pt 1):115811. PMID: 41232362 -
Int Immunopharmacol
Curcumenol exerts anti-pulmonary fibrosis effects through modulation of the immune signature target SPP1: based on comprehensive bioinformatics and experiments validation. [Abstract]2025 Sep 5:165:115469. PMID: 40913866 -
Int Immunopharmacol
Pirfenidone ameliorates early pulmonary fibrosis in LPS-induced acute respiratory distress syndrome by inhibiting endothelial-to-mesenchymal transition via the Hedgehog signaling pathway. [Abstract]2022 Aug:109:108805. PMID: 35504205 -
Pharm Res
Thermodynamic, Spatial and Methodological Considerations for the Manufacturing of Therapeutic Polymer Nanoparticles. [Abstract]2020 Feb 24;37(3):59. PMID: 32095934 -
J Inflamm Res
Qimai Feiluoping Decoction Inhibits EndMT to Alleviate Pulmonary Fibrosis by Reducing PI3K/AKT/mTOR Pathway-Mediated the Restoration of Autophagy. [Abstract]2025 Jun 26:18:8447-8475. PMID: 40589610 -
-
Sci Rep
2025 Aug 1;15(1):28071. PMID: 40751072 -
Biomedicines
Local Delivery of Pirfenidone by PLA Implants Modifies Foreign Body Reaction and Prevents Fibrosis. [Abstract]2021 Jul 21;9(8):853. PMID: 34440057 -
ACS Pharmacol Transl Sci
Hydronidone Mitigates Pulmonary Fibrosis by Regulating the TGF-β/Smad2/3 Axis in in Vitro and in Vivo Models. [Abstract]2025 Oct 6;8(11):3984-4000. PMID: 41262559 -
ACS Pharmacol Transl Sci
NARI-29: A Novel Epalrestat Derivative Attenuates Pulmonary Fibrosis by Modulating the TGF-β/Smad Signaling. [Abstract]2025 May 9;8(6):1610-1626. PMID: 40534681 -
Exp Cell Res
m6A methyltransferase ZC3H13 improves pulmonary fibrosis in mice through regulating Bax expression. [Abstract]2024 Sep 20:114255. PMID: 39307407 -
Mol Med Rep
Exosomes from miR-29a-modified adipose-derived mesenchymal stem cells reduce excessive scar formation by inhibiting TGF-β2/Smad3 signaling. [Abstract]2021 Nov;24(5):758. PMID: 34476508 -
Basic Clin Pharmacol Toxicol
7,8-Dihydroxyflavone Suppresses Experimental Pulmonary Fibrosis by Inhibiting Fibroblast-to-Myofibroblast Transformation and Epithelial-Mesenchymal Transition. [Abstract]2026 Jan;138(1):e70158. PMID: 41347324 -
Pathol Res Pract
Combined treatment of tacrolimus and pirfenidone effectively improves BLM-induced pulmonary fibrosis in mice by inhibiting the TGFβ1/Smad2/3 signaling. [Abstract]2025 Aug:272:156095. PMID: 40617191 -
Pathol Res Pract
Overexpression of ERβ inhibits the proliferation through regulating TNG-β signaling pathway in osteosarcoma. [Abstract]2019 Oct;215(10):152568. PMID: 31383536 -
Naunyn Schmiedebergs Arch Pharmacol
Therapeutic use of fisetin and pirfenidone combination in bleomycin-induced pulmonary fibrosis in adult male albino rats. [Abstract]2025 Feb;398(2):1665-1679. PMID: 39162796 -
Pancreatology
Pirfenidone ameliorates chronic pancreatitis in mouse models through immune and cytokine modulation. [Abstract]2022 Jun;22(5):553-563. PMID: 35570091 -
Parasitology
A combination of pirfenidone and TGF-β inhibition mitigates cystic echinococcosis-associated hepatic injury. [Abstract]2021 Jun;148(7):767-778. PMID: 33583470 -
Biomed Res Int
Protective Effects of the Wenfei Buqi Tongluo Formula on the Inflammation in Idiopathic Pulmonary Fibrosis through Inhibiting the TLR4/MyD88/NF- κ B Pathway. [Abstract]2022 Feb 7;2022:8752325. PMID: 35178456 -
Radiat Res
Antifibrotic Agent Pirfenidone Protects against Development of Radiation-Induced Pulmonary Fibrosis in a Murine Model. [Abstract]2018 Oct;190(4):396-403. PMID: 30016220
Pirfenidone purchased from MedChemExpress. Usage Cited in: Radiat Res. 2018 Oct;190(4):396-403. [Abstract]
Western blots are shown of collagen I, collagen III, TGF-b1, p-Smad3 and Smad3 proteins in lung tissue homogenates from different groups.
-
Int J Ophthalmol
Pirfenidone Attenuates the EMT Process and the Secretion of VEGF in TGF- β 2-Induced ARPE-19 Cells via Inhibiting the Activation of the NF- κ B/Snail Signaling Pathway. [Abstract]2023 Jan 30:2023:4798071. PMID: 36756225 -
Integr Biol (Camb)
2022 Mar 21;14(1):1-12. PMID: 35184163 -
-
-
-
bioRxiv
Pirfenidone treatment attenuates fibrosis in autosomal dominant polycystic kidney disease. [Abstract]2025 Aug 29:2025.08.25.672225. PMID: 40909512 -
-
-
-
-
-
-
-
Oncotarget
Limited fibrosis accompanies triple-negative breast cancer metastasis in multiple model systems and is not a preventive target. [Abstract]2018 May 4;9(34):23462-23481. PMID: 29805748
溶剤 & 溶解度
DMSO : ≥ 100 mg/mL (539.90 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 12.5 mg/mL (67.49 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 9.09 mg/mL (49.08 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Add each solvent one by one: Saline
Solubility: 6.67 mg/mL (36.01 mM); Clear solution; Need ultrasonic
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 30.3 mg/mL (163.59 mM); Clear solution; Need ultrasonic
Add each solvent one by one: 0.5% CMC/saline water
Solubility: 10 mg/mL (53.99 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
プロトコル
HLECs are seeded in 96-well plates (1×104 cells/well) for 24 hours in α-MEM/10% FBS/1%NEAA, and are cultured in stationary tubes in serum-free medium for 24 hours. And then the culture medium is removed and cells are bathed in α-MEM with 10% FBS and 1% NEAA supplemented with 0, 0.01, 0.1, 0.2, 0.3, 0.5, or 1 mg/mL Pirfenidone for 0, 4, 12, 24, 48, or 72 hours. After incubation with 180 µL α-MEM and 20 µL of 5 mg/mL MTT for 4 hours at 37°C, the MTT solution is discarded. The Formosan precipitates are dissolved in 180 µL DMSO by agitating the dishes for 10 minutes at 200 rpm on an orbital shaker. The absorbance at 490 nm in each well is read with a micro plate reader. We further examined the effects of PFD by refining the concentrations at 0.2, 0.25, 0.3, 0.4, 0.5 and 0.6 mg/mL using the MTT assay[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[4]
Nine-week-old female C57BL/6 mice are used. Pirfenidone is administered orally for 14 days after osmotic pump implantation. The volume of administration is determined according to body weight. Animals are allocated into 4 groups (n=6/group): normal control, BLM, Pirfenidone (300 mg/kg/day), and BLM + Pirfenidone. The Pirfenidone dose is selected according to a report published elsewhere. Pirfenidone is also administered in a therapeutic setting beginning at day 10 to assess the effect of the drug on the fibrotic phase of BLM model mice.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
純度とドキュメンテーション
-
データシート (283 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Burghardt I, et al. Pirfenidone inhibits TGF-beta expression in malignant glioma cells. Biochem Biophys Res Commun. 2007 Mar 9;354(2):542-7. [Content Brief]
[2]. Nakazato H, et al. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol. 2002 Jun 20;446(1-3):177-85. [Content Brief]
[3]. Yang Y, et al. Inhibition of Pirfenidone on TGF-beta2 induced proliferation, migration and epithlial-mesenchymal transitionof human lens epithelial cells line SRA01/04. PLoS One. 2013;8(2):e56837. [Content Brief]
[4]. Inomata M, et al. Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. Respir Res. 2014 Feb 8;15:16. [Content Brief]
[5]. Brooks D, et al. Limited fibrosis accompanies triple-negative breast cancer metastasis in multiple model systems and is not a preventive target. Oncotarget. 2018 May 4;9(34):23462-23481. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 5.3990 mL | 26.9949 mL | 53.9898 mL | 134.9746 mL |
| 5 mM | 1.0798 mL | 5.3990 mL | 10.7980 mL | 26.9949 mL | |
| 10 mM | 0.5399 mL | 2.6995 mL | 5.3990 mL | 13.4975 mL | |
| 15 mM | 0.3599 mL | 1.7997 mL | 3.5993 mL | 8.9983 mL | |
| 20 mM | 0.2699 mL | 1.3497 mL | 2.6995 mL | 6.7487 mL | |
| 25 mM | 0.2160 mL | 1.0798 mL | 2.1596 mL | 5.3990 mL | |
| 30 mM | 0.1800 mL | 0.8998 mL | 1.7997 mL | 4.4992 mL | |
| 40 mM | 0.1350 mL | 0.6749 mL | 1.3497 mL | 3.3744 mL | |
| 50 mM | 0.1080 mL | 0.5399 mL | 1.0798 mL | 2.6995 mL | |
| 60 mM | 0.0900 mL | 0.4499 mL | 0.8998 mL | 2.2496 mL | |
| DMSO | 80 mM | 0.0675 mL | 0.3374 mL | 0.6749 mL | 1.6872 mL |
| 100 mM | 0.0540 mL | 0.2699 mL | 0.5399 mL | 1.3497 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz